You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Generation of tumor antigen-specific CD4+ and CD8+ T cells by simultaneous MHC-I and -II epitope presentation in vitro and in vivo
  1. Carina Wehner1,
  2. Christian Ellinger1,
  3. Silke Raffegerst1,
  4. Susanne Wilde1,
  5. Barbara Mosetter2,
  6. Judith Eckl1,
  7. Bernhard Frankenberger2,
  8. Manon Weis1,
  9. Giulia Longinotti1,
  10. Nadja Sailer1,
  11. Dolores J Schendel1 and
  12. Slavoljub Milosevic1
  1. Aff1 Trianta Immunotherapies GmbH - a subsidiary of Medigene AG Germany
  2. Aff2 Institute of Molecular Immunology/Helmholtz Center Munich Germany

https://doi.org/10.1186/2051-1426-2-S3-P65

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    In recent years, activation of the patient's immune system to defend against tumors was demonstrated to be a promising alternative strategy to classical cancer treatments. Dendritic cells (DCs) can present antigens on MHC-II and -I leading to the activation of CD4+ or CD8+ T cells, respectively. Stimulated CD4+ T cells act as helper cells for cytotoxic CD8+ T cells to kill tumor cells by mediating strong proliferation and licensing DCs, increasing their presentation capacity. Tumors bearing MHC-II molecules can also be directly destroyed by cytotoxic CD4+ T cells. As an efficient anti-tumor response strongly depends on the interplay of DCs, CD4+ and CD8+ T cells, these three cell types are considered to be essential for successful immunotherapy design.

    In clinical trials, DCs were either endogenously or exogenously loaded with tumor antigens for the presentation on MHC-I rather MHC-II. As the antigen presentation pathways differ, a simultaneous loading of MHC-I and -II was suboptimal. To overcome this obstacle, we used a signaling sequence (CrossTAg) to force MHC-II cross-presentation of tumor-associated antigens (TAAs) encoded by in vitro transcribed (ivt) RNA. Subsequently, peripheral blood lymphocytes were primed by DCs expressing TAAs on MHC-I and -II enabling activation and interaction of CD4+ and CD8+ T cells. By this approach, we were able to induce and identify TAA-specific CD4+ and CD8+ T cells in the same experiment.

    In addition, superior induction efficiency of DCs loaded with CrossTAg-TAA-ivt RNA compared to conventional TAA-ivt RNA was shown in the humanized NOD/scid IL2Rgnull (NSG) mouse model. NSG mice were engrafted with human peripheral blood mononuclear cells (PBMC) and vaccinated twice with DCs either transfected with CrossTAg-TAA-ivt RNA or conventional TAA-ivt RNA. Reisolated PBMC of mice vaccinated with CrossTAg-TAA-ivt RNA transfected DCs showed higher numbers of antigen-specific CD8+ T cells and stronger activation/cytotoxic activity against tumor cells.

    These in vitro and in vivo data illustrate the benefits of loading DCs with CrossTAg-linked target antigens as CD8+ and CD4+ T cells can be induced side by side allowing interactions and T cell help.